JFJun Fukihara

Jun Fukihara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jun Fukihara has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Tomoki Kimura

    Department of Respiratory Medicine and Allergy Tosei General Hospital Seto Japan

    6 shared publications
  • Kensuke Kataoka

    Department of Respiratory Medicine and Allergy Tosei General Hospital Seto Japan

    5 shared publications
  • Yoshinori Hasegawa

    Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan

    5 shared publications
  • Yasuhiro Kondoh

    Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Aichi, Japan

    4 shared publications
  • Toshiaki Matsuda

    Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan

    3 shared publications
  • Toshiki Yokoyama

    Department of Respiratory Medicine and Allergy, Tosei General Hospital, Seto, Japan

    3 shared publications

Latest Publications

  • Impact of Pulmonary Artery Pressure on the Response to Oxygen Administration for Exertional Desaturation in Interstitial Lung Disease

    by Jun Hirasawa, Ryo Teramachi, Jun Fukihara, Fumiko Watanabe, Tomoya Ogawa, Reoto Takei, Yasuhiko Yamano, Kensuke Kataoka, Kazuaki Soejima, Tomoki Kimura, et al.

    Background and Objective: Patients with interstitial lung disease (ILD) often experience exertional desaturation even without resting hypoxemia, resulting in limited exercise capacity. While oxygen administration can extend exercise time in a majority of patients with ILD, the factors determining the oxygen effects are unclear. We aimed to investigate the clinical significance of respiratory and pulmonary haemodynamic parameters for the oxygen effects on exercise time in patients with ILD.Methods: We retrospectively analysed patients with ILD who underwent comprehensive evaluation including right heart catheterisation from 2017 to 2021. Patients were divided into oxygen responders, defined as an improvement of at least 100 s or 33% in exercise time with oxygen supplementation compared with medical air inhalation, and non‐responders. Univariate and multivariate logistic regression analyses were conducted to evaluate significant factors for oxygen responders.Results: Among 86 patients, 50 (58.1%) were oxygen responders. Pulmonary functional tests and ventilation parameters at cardiopulmonary exercise testing were similar between the groups. Mean pulmonary arterial pressure (mPAP) (21 mmHg vs. 19 mmHg, p = 0.049) was higher in oxygen responders. Univariate logistic analysis demonstrated that the ILD‐Gender‐Age‐Physiology index, mPAP, 6‐min walking distance, peak work rate, and lowest ventilatory equivalent for carbon dioxide were significant variables for oxygen effects on exercise time. Multivariate analysis demonstrated that elevated mPAP was independently associated with the oxygen effects on exercise time.Conclusion: Approximately 60% of the patients with ILD who experienced exertional desaturation without resting hypoxemia were oxygen responders. mPAP was associated with the oxygen effects on exercise time. image


  • Clinical burden of immune checkpoint inhibitor-induced pneumonitis

    by Koji Sakamoto, Jun Fukihara, Masahiro Morise, Naozumi Hashimoto


  • Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non–Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors

    by Jun Fukihara, Koji Sakamoto, Junji Koyama, Takayasu Ito, Shingo Iwano, Masahiro Morise, Masahiro Ogawa, Yasuhiro Kondoh, Tomoki Kimura, Naozumi Hashimoto, et al.


  • Open Access

    Acute exacerbations of fibrotic interstitial lung diseases

    by Atsushi Suzuki, Yasuhiro Kondoh, Kevin K. Brown, Takeshi Johkoh, Kensuke Kataoka, Junya Fukuoka, Tomoki Kimura, Toshiaki Matsuda, Toshiki Yokoyama, Jun Fukihara, et al.

    Background and objective: Acute exacerbation (AE) is a severe complication of idiopathic pulmonary fibrosis (AE‐IPF). In 2016, an international working group revised its definition and diagnostic criteria; however, few studies have assessed the frequency and prognosis of AE in patients with other fibrotic interstitial lung diseases (FILD).Methods: We used data from 1019 consecutive interstitial lung disease (ILD) patients initially evaluated between January 2008 and July 2015. All subject diagnoses were made by multidisciplinary discussion in December 2018. ILD was categorized as IPF (n = 462) and other FILD which included non‐specific interstitial pneumonia (n = 22), chronic hypersensitivity pneumonitis (n = 29), connective tissue disease‐associated ILD (n = 205) and unclassifiable ILD (n = 209). Using the 2016 definition of AE‐IPF, we identified all subjects with an AE.Results: During the observational period, 193 patients experienced a first AE (AE‐FILD n = 69, AE‐IPF n = 124). The time to first AE was significantly longer in FILD than IPF (log‐rank test, P < 0.001). After adjusting for potentially influential confounders, FILD remained a significant predictor of longer time to first AE compared with IPF (hazard ratio: 0.453; 95% CI: 0.317–0.647, P = 0.006). In a multivariate Cox proportional analysis, baseline disease severity was closely associated with the incidence of AE‐ILD. Even after adjustment for other clinical variables, AE had a negative impact on overall survival. AE‐FILD and AE‐IPF showed similar poor short‐term outcomes.Conclusion: All forms of ILD are at risk of AE and have a similar outcome to AE‐IPF.


  • Open Access

    Lung Metastases from Bile Duct Adenocarcinoma Mimicking Chronic Airway Infection and Causing Diagnostic Difficulty

    by Mitsuo Sato, Shotaro Okachi, Jun Fukihara, Yoshie Shimoyama, Keiko Wakahara, Toshihiro Sakakibara, Tetsunari Hase, Yasuharu Onishi, Yasuhiro Ogura, Osamu Maeda, et al.

    We herein report a case of lung metastases with unusual radiological appearances that mimicked those of chronic airway infection, causing diagnostic difficulty. A 60-year-old woman who underwent liver transplantation from a living donor was incidentally diagnosed with bile duct adenocarcinoma after a histopathological analysis of her explanted liver. Six months later, chest computed tomography (CT) revealed bilateral bronchogenic dissemination that had gradually worsened, suggesting chronic airway infection. A biopsy with bronchoscopy from a mass lesion beyond a segmental bronchus revealed adenocarcinoma identical to that of her bile duct adenocarcinoma, leading to the diagnosis of multiple lung metastases from bile duct adenocarcinoma.

  • Open Access

    Hemosiderin-laden macrophages are an independent factor correlated with pulmonary vascular resistance in idiopathic pulmonary fibrosis: a case control study

    by Jun Fukihara, Hiroyuki Taniguchi, Masahiko Ando, Yasuhiro Kondoh, Tomoki Kimura, Kensuke Kataoka, Taiki Furukawa, Takeshi Johkoh, Junya Fukuoka, Koji Sakamoto, et al.

    Increases in hemosiderin-laden macrophages (HLM) are reported to be observed in idiopathic pulmonary fibrosis (IPF). According to a recent study, significant correlation between hemosiderin deposition in the lung tissue of IPF and pulmonary hypertension evaluated by echocardiography has been suspected. In this study, we aimed to evaluate whether HLM in bronchoalveolar lavage fluid (BALF) is a factor correlated with pulmonary hemodynamic parameters evaluated by right heart catheterization in patients with IPF. Initial data from 103 consecutive patients with IPF who underwent surgical lung biopsy between November 2007 and March 2014 were retrospectively analyzed. The “HLM score” of BALF was established by dividing the number of Perls’ Prussian blue stain positive macrophages by the total number of macrophages counted. BALF showed an elevated HLM score (38.2%). Right heart catheterization revealed mean pulmonary arterial pressure (mPAP) of 16.3 mmHg and pulmonary vascular resistance (PVR) of 1.55 Wood units. HLM score was positively correlated with mPAP (ρ = 0.204; p = 0.038) and PVR (ρ = 0.349, p < 0.001). In multivariate analysis, 6-min walk distance (standardized partial regression coefficient [β], −0.391; p < 0.001), minimum oxygen saturation during 6-min walk distance (β, −0.294; p = 0.001) and HLM score (β, 0.265; p = 0.002) were independently correlated with PVR. HLM score in BALF is an independent factor correlated with PVR in patients with IPF.


  • Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis

    by Jun Fukihara, Yasuhiro Kondoh

    Nintedanib is a new anti-fibrosis agent that is an intracellular tyrosine kinase inhibitor targeting platelet derived growth factor receptor, fibroblast growth factor receptor and vascular endothelial growth factor receptor. Although nintedanib is attracting much attention as a new treatment option for patients with idiopathic pulmonary fibrosis (IPF), the clinical evidence is limited mainly to the results from the dose-deciding phase II TOMORROW trial and phase III INPULSIS trials, which evaluated efficacy and safety of nintedanib for patients with IPF, prespecified subgroup analyses, pooled analyses and meta-analyses derived from those trials. Areas covered: In this document, we mainly reviewed reports on working mechanisms of nintedanib, and efficacy and safety of nintedanib for patients with IPF. The literature search was undertaken using Pub Med. Expert commentary: It is unknown whether the efficacy of nintedanib in patients enrolled in the clinical trials will be the same for the entire spectrum of patients, including patients unfit for the clinical trials due to age, severity, timing of IPF diagnosis or diagnosis of interstitial pneumonias other than IPF. Sufficient consideration should be given when selecting candidates for nintedanib in the real world.


  • Open Access

    Pulmonary hypertension associated with obliterative phlebitis in IgG4-related lung disease

    by Jun Fukihara, Yasuhiro Kondoh, Hiroyuki Taniguchi, Tomoki Kimura, Kensuke Kataoka, Toshiaki Matsuda, Toshiki Yokoyama, Kenzo Ono, Yukio Kashima, Junya Fukuoka

    Pulmonary hypertension can be caused by obliterative phlebitis in patients with IgG4-related lung diseasehttp://ow.ly/EEjvE


  • Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

    by Jun Fukihara, Naohiro Watanabe, Hiroyuki Taniguchi, Yasuhiro Kondoh, Tomoki Kimura, Kensuke Kataoka, Toshiaki Matsuda, Toshiki Yokoyama, Yoshinori Hasegawa

    Background: The presence of EGFR (epidermal growth factor receptor) mutations is a robust predictor of EGFR tyrosine kinase inhibitor (TKI) responsiveness. Predictors of EGFR-TKI responsiveness in EGFR-mutant non-small cell lung cancer (NSCLC) patients, however, have not been well investigated. The purpose of this study is to examine predictors of EGFR-TKI responsiveness in EGFR-mutant NSCLC patients. Patients and Methods: Seventy EGFR-mutant NSCLC patients who received EGFR-TKIs in our institution between April 2007 and March 2013 were analyzed retrospectively. Results: The objective response rate was 50.0% (95% confidence interval, CI, 38.6-61.4%) and the disease control rate was 91.4% (95% CI, 82.5-96.0%). The median progression-free survival (PFS) and overall survival were 9.0 (95% CI, 3.92-14.08) and 20.8 months (95% CI, 14.56-27.04), respectively. In multivariate analysis, adenocarcinoma (hazard ratio, HR, 12.25; 95% CI, 37.7-41.10; p < 0.001) and major mutations (deletions in exon 19 and L858R point mutation in exon 21; HR, 2.46; 95% CI, 1.14-5.28; p = 0.022) were significant predictors of longer PFS. Conclusion: Major mutations and adenocarcinoma histology were independent predictors of better treatment outcome in EGFR-mutant NSCLC patients who received EGFR-TKIs. Further well-controlled prospective studies are warranted to confirm our findings.